Fluciclovine F 18, also known as Axumin, is a radiopharmaceutical used in positron emission tomography (PET) imaging to detect and localize recurrent prostate cancer. This drug works by targeting amino acid transporters that are overexpressed in prostate cancer cells, allowing for more accurate imaging of the disease.

Fluciclovine F 18 is administered intravenously and quickly accumulates in prostate cancer cells, making it an effective tool for detecting cancer recurrence in patients who have previously undergone treatment. This drug is particularly useful in cases where traditional imaging techniques, such as CT scans or MRI, may not provide clear results.

As with any medication, there are potential side effects associated with Fluciclovine F 18. These may include mild reactions at the injection site, such as redness or swelling, as well as rare allergic reactions. It is important for patients to inform their healthcare provider of any allergies or medical conditions before undergoing a PET scan with Fluciclovine F 18.

Overall, Fluciclovine F 18 has been shown to be a valuable tool in the management of recurrent prostate cancer, providing clinicians with important information to guide treatment decisions. If you have any questions or concerns about this drug or its use in your specific situation, please do not hesitate to speak with your healthcare provider. They can provide you with more information and help determine if Fluciclovine F 18 is the right choice for you.